57939-04-5

Basic information

• Product Name: 1-(1H-Pyrazol-1-yl)propan-2-aMine
• Synonyms: 3-nitro-4-phenoxy-5-sulfamoylbenzoic acid methyl ester
• CAS NO: 57939-04-5
• Molecular Formula: C₁₄H₁₂N₂O₇S
• Molecular Weight: 352.31928
• Mol File: 57939-04-5.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-(1H-Pyrazol-1-yl)propan-2-aMine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(1H-Pyrazol-1-yl)propan-2-aMine(57939-04-5)
• EPA Substance Registry System: 1-(1H-Pyrazol-1-yl)propan-2-aMine(57939-04-5)

Safety Data

• Hazardous Substances Data: 57939-04-5(Hazardous Substances Data)

Usage

Description

1-(1H-Pyrazol-1-yl)propan-2-aMine, also known as 3-(1H-pyrazol-1-yl)propan-1-amine, is a chemical compound with the molecular formula C6H10N4. It is a derivative of pyrazole and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 1-(1H-Pyrazol-1-yl)propan-2-aMine is a white to off-white solid with a melting point of 47-49°C. It is primarily utilized in the research and development of various organic compounds due to its versatile reactivity and utility in the production of diverse chemical structures. As a pyrazole derivative, it exhibits interesting biological activities and potential applications in drug discovery and development.

Uses

Used in Pharmaceutical Industry:
1-(1H-Pyrazol-1-yl)propan-2-aMine is used as an intermediate for the synthesis of various pharmaceuticals. Its versatile reactivity and utility in the production of diverse chemical structures make it a valuable component in the development of new drugs.
Used in Agrochemical Industry:
1-(1H-Pyrazol-1-yl)propan-2-aMine is also used as an intermediate in the synthesis of agrochemicals, contributing to the development of new compounds for agricultural applications.
Used in Research and Development:
1-(1H-Pyrazol-1-yl)propan-2-aMine is used as a research tool for the development of various organic compounds. Its interesting biological activities and potential applications in drug discovery make it a promising candidate for further investigation and development in the scientific community.

Upstream product

• 67-56-1 methanol 
• 28328-53-2 3-nitro-4-phenoxy-5-sulfamoylbenzoic acid 
• 108-95-2 phenol 
• 22892-96-2 4-chloro-3-nitro-5-sulfamoylbenzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 60376-73-0 3-(dimethylaminomethylenesulfamoyl)-5-nitro-4-phenoxybenzoic acid methyl ester 
• 60376-74-1 5-amino-3-(dimethylaminomethylenesulfamoyl)-4-phenoxybenzoic acid methyl ester 
• 1357458-70-8 3-(bis(cyclopropylmethyl)amino)-4-phenoxy-5-sulfamoylbenzoic acid 
• 1357465-05-4 3-(dimethylaminomethylene-sulfamoyl)-5-dipentylamino-4-phenoxy-benzoic acid methyl ester 
• 1357458-81-1 3-dipentylamino-4-phenoxy-5-sulfamoyl-benzoic acid 
• 1411657-52-7 methyl 3-(di(butyl-d9)amino)-4-phenoxy-5-sulfamoylbenzoate 
• 1411657-14-1 3-(di(butyl-d9)amino)-4-phenoxy-5-sulfamoylbenzoic acid 
• 56106-57-1 3-amino-4-phenoxy-5-sulphamoylbenzoic acid methyl ester 
• 57939-09-0 4-phenoxy-3-(piperidin-1-yl)-5-sulfamoylbenzoic acid 
• 1431505-42-8 methyl 3-(N-((dimethylamino)methylene)sulfamoyl)-4-phenoxy-5-(piperidin-1-yl)benzoate 
• 1431501-29-9 C₂₂H₂₈N₂O₅S 

Relevant articles and documents

DEUTERATED N-BUTYL BUMETANIDE

The present invention provides a compound of Formula I: as defined herein, or a pharmaceutically acceptable salt thereof.

ARYLSULFONAMIDE DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

The present invention provides acylsulfonamides including bumetanide derivatives and compositions comprising such analogs. The present invention also provides pharmaceutical compositions containing these compounds and methods for their use. All of these analogs are particularly useful for the treatment and/or prophylaxis of conditions that involve the Na+K+Cl- co-transporter or GABAA receptor including but not limited to addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders (autism), bipolar disorder, cancer, the improvement of cognitive function, cognitive impairment, cognitive dysfunction, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, Parkinson's disease, periodic limb movement disorder (PLMD), personality disorders, postherpetic neuralgia, psychosis, restless legs syndrome (RLS), schizophrenia, seizure disorders, spasticity, tinnitus, and withdrawal syndromes.